A recent international report of 64 studies shows Ivermectin has an 86% success rate as a prophylaxis and a 67% success rate in early treatment of coronavirus.
The results mirror the over 290 studies on hydroxychloroquine that have been reported over the past year.
The CDC, Dr. Fauci and the FDA ridiculed the use of the drugs to treat the China Virus despite their continued effectiveness in peer-reviewed studies.
The Gateway Pundit has reported extensively on the CDC’s decisions that resulted in the deaths of thousands of Americans.
Now, as the vaccines continue to fail the US government is purchasing one billion dollars worth of the expensive treatment drug molnupiravir — similar to HCQ and Ivermectin but more expensive — from Merck and Co. Inc and partner Ridgeback Biotherapeautics.
It’s another big payday for Big Pharma.
US News reported:
The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday.
The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.
That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.
The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.
The Gateway Pundit is always committed to ensuring your voice can and will be heard. To reinforce that commitment, we are switching our commenting platform to Insticator. Don’t worry! All you have to do is create a commenting account with Insticator, and then you will be able to link past comments into your new Insticator account. For more information, we’ve written an article that you can read HERE. If you have any feedback or questions about your Insticator commenting account, please email them at: [email protected].